June 22, 2021 | Jen Temple, Head of Communications | Reading Time: < 1 minute
Last year, by Precision Oncology News’ count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019. Although more and more biomarker-informed therapies are being developed and launched on the market, not all patients have access to them due to numerous barriers, among them difficulties accessing genetic testing, limited physician expertise, challenges setting up clinical trials in the community, and reimbursement pressures.
Patients’ social determinants of health also continue to influence whether they receive, or are even offered, biomarker testing and downstream treatment options.
In this panel, experts in the community treating diverse populations and tracking access challenges discuss the difficulties they are seeing and the solutions they’re working on to improve equity in precision oncology.
Kellie Jack of Weill Cornell Medicine, Raymond Osarogiagbon of Baptist Cancer Center, Rachit Kumar of Maine General Medical Center, and Greg Tranah of Sutter Health bring wide-ranging perspectives from small and large health systems across the U.S.
June 5, 2023
To discuss the development of the Endometrial ProMisE Molecular Classifier, and the new NSMP study further, we are delighted to have Dr. Jessica McAlpine and Dr. Amy Jamieson, esteemed gynecological cancer surgeons at Vancouver General Hospital, who have been instrumental in the development and implementation of this innovative tool.
May 15, 2023
We were grateful for the opportunity to attend and present at the AACR Annual Meeting last week, where three of our scientists highlighted some of the exciting work happening in our Vancouver lab.
March 28, 2023
Imagia Canexia Health announced that three abstracts highlighting the company’s new learnings and tools will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.